IL2 and acute myeloid leukemia: In addition, induction of NK cell NCR expression during initial treatment cycles coincided with reduced risk of relapse.16,55 More recent analyses of the Re:Mission trial data investigated the impact of refined aspects of NK cell biology and showed that genetic determinants leading to an NK cell repertoire of immature, cytokine-responsive NK cells were associated with favorable clinical outcome.61, , –64Figure 1 depicts the proposed antileukemic mechanism of HDC/IL-2 in the AML remission maintenance setting.